Anaplastic thyroid carcinoma (ATC) is a highly aggressive and treatment-resistant form of thyroid cancer, characterized by poor prognosis, rapid metastasis, and resistance to conventional therapies. Current treatment options, including surgery, chemotherapy, and radiation, are often ineffective in controlling the disease, underscoring the urgent need for novel therapeutic approaches. Nanotechnology has emerged as a promising strategy to overcome these challenges, offering innovative solutions for targeted drug delivery and noninvasive therapeutic modalities. This review explores the latest advancements in nanotechnology-driven strategies for treating ATC, with a particular focus on noninvasive therapies such as sonodynamic therapy and nano-pulse stimulation, as well as the development of nanomaterial-based drug delivery systems. These systems, including RNA-based nanocarriers, radionuclide-labeled nanoparticles, and nanoclay-based delivery systems, provide enhanced specificity and efficacy, overcoming the limitations of traditional treatments. Additionally, dual-modality theranostic systems, which combine diagnostic imaging and therapeutic payloads, hold great promise in improving early detection and real-time treatment monitoring. Despite the promising preclinical results, challenges such as tumor heterogeneity, drug resistance, and biocompatibility of nanomaterials remain in the clinical use. This review provides a comprehensive overview of the potential of nanotechnology to revolutionize the treatment of ATC, offering new hope for patients with this highly aggressive malignancy.
Ma et al. (Sat,) studied this question.